Usually not in the way a blood stem cell transplant does. For TEMCELL in Japan and Ryoncil in the United States, the approved treatment instructions do not specify matching the patient’s human leukocyte antigen (HLA) type to the MSC donor’s type. That does not mean the donor is untested: TEMCELL’s review explicitly lists donor HLA and blood-group testing. Recording a donor’s type is different from selecting a donor who matches the patient 000215658.pdfFda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatricDownload.
Allogeneic MSCs are mesenchymal stromal cells collected from another person. The answer for a particular treatment depends on the exact product or study protocol. These two approved products treat acute graft-versus-host disease (GVHD), a complication of blood stem cell transplantation; their approvals are not a blanket authorization for donor MSC treatment of other conditions 000215658.pdfDownload.

HLA typing is not the same as matching
HLA molecules help the immune system recognize cells. Typing identifies someone’s HLA variants. Matching compares donor and recipient types to guide donor selection. An anti-HLA antibody test asks a different question: whether the patient has antibodies against HLA targets. Antibodies directed against a particular donor are called donor-specific antibodies, or DSAs Np24365_donor selection guidelines_2025 07 23_digital.pdf.
For an unrelated-donor blood stem cell transplant, an 8/8 HLA match at HLA-A, -B, -C and -DRB1 remains an important donor-selection option. It is not the only option: NMDP’s 2025 guidance also addresses mismatched and half-matched donors, with selection depending partly on the GVHD-prevention regimen. These transplant rules should not be copied directly into an MSC infusion decision Np24365_donor selection guidelines_2025 07 23_digital.pdf.
The document detail matters. Table 3.3 of TEMCELL’s PMDA review lists HLA, ABO and Rh among donor tests. That is evidence of donor characterization, not a requirement to find an HLA-matched MSC donor for each recipient. A clinic saying “no matching needed” should still be able to explain which donor tests and recipient assessments its protocol uses 000215658.pdf.
Why unmatched MSCs are not immune-invisible
TEMCELL’s laboratory studies found weak HLA class I expression, no detectable class II expression at baseline, and no detectable CD40, CD80 or CD86 costimulatory molecules. Exposure to interferon-gamma increased class I expression and induced class II expression. This profile helps explain the rationale for using unmatched cells, but it does not establish that immune reactions cannot occur 000215658.pdf.
PMDA described the proposed immunological mechanism as an inference requiring further investigation. Ryoncil’s prescribing information likewise says its mechanism of action is not clear, although it may involve immune modulation. “No routine matching requirement” is therefore more accurate than “no rejection risk” 000215658.pdfDownload.
What the approved products show
| Feature | TEMCELL HS | Ryoncil |
|---|---|---|
| Approval | Japan, 18 September 2015 000215658.pdf | United States, 18 December 2024 Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric |
| Cells and route | Donor bone marrow-derived MSCs, intravenous infusion 000215658.pdf | Donor bone marrow-derived MSCs, intravenous infusion Download |
| Approved use | Acute GVHD after hematopoietic stem cell transplantation; precautions specify inadequate response to corticosteroids 000215658.pdf | Steroid-refractory acute GVHD in pediatric patients aged 2 months and older Download |
| Recipient–donor HLA matching | Not specified as a treatment requirement in the approval documents 000215658.pdf | Not specified as a treatment requirement in the prescribing information Download |
| Initial schedule | 2 million cells/kg, twice weekly for 4 weeks; additional weekly treatment may be used according to response 000215658.pdf | 2 million cells/kg, twice weekly for 4 weeks; subsequent treatment depends on day-28 response or recurrence Download |
| Pivotal study result | Single-arm phase 2/3 study, 25 patients: complete response lasting at least 28 days, 48.0% (95% CI 27.8–68.7) 000215658.pdf | Single-arm study, 54 treated patients: overall response at day 28, 70% (95% CI 56.4–82.0) Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric |
These percentages are not a head-to-head comparison: TEMCELL’s endpoint was a sustained complete response, while Ryoncil’s included complete and partial responses at day 28. Neither pivotal study had a concurrent control group. Ryoncil’s median response duration was 54 days, measured from day-28 response to progression, new systemic GVHD therapy or death 000215658.pdfFda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.
PMDA also reviewed a separate phase 3 Prochymal trial in 260 patients with steroid-refractory acute GVHD. Complete response lasting at least 28 days occurred in 60/173 patients receiving Prochymal (34.7%) and 26/87 receiving placebo (29.9%); the difference was not statistically significant (p = 0.423). This was supporting evidence involving related MSC technology, not a randomized comparison of matched versus unmatched donors 000215658.pdf.
When antibody testing deserves discussion
You have known anti-HLA antibodies
FDA’s Ryoncil review states that anti-HLA antibodies were not tested in the pivotal MSB-GVHD001 study. Their effect on clinical response could therefore not be assessed. The review identifies uncertainty about anti-donor antibodies and describes enhanced safety surveillance for these events. It does not establish a universal pre-infusion antibody-testing schedule for all MSC recipients Download.
Human evidence shows that sensitization can occur. POSEIDON was a small, open-label phase 1/2 study treating 30 adults with ischemic cardiomyopathy, including 15 who received donor MSCs by injection into heart muscle. Eight of 27 patients tested had HLA sensitization at baseline. At six months, two donor-MSC recipients had newly detected low-level class I antibodies; only one had donor-specific antibodies. These findings do not provide a reliable risk estimate for intravenous MSC products or repeated clinic infusions PMC4762261.
You may need a blood stem cell transplant
Tell the transplant team about any proposed donor-cell treatment before it happens. NMDP recommends avoiding transplant donors with mismatched HLA targets recognized by the patient’s DSAs. That makes new sensitization potentially relevant to a future donor search, even though MSC infusion and blood stem cell transplantation are different procedures Np24365_donor selection guidelines_2025 07 23_digital.pdf.
You are considering repeated doses
Ask how the clinician would assess a new antibody result and whether it would change further treatment. Ryoncil’s instructions distinguish weekly extension after partial or mixed response from another twice-weekly course after recurrence following complete response. A private clinic’s repeated-dose package should not be assumed to have the same evidence or monitoring requirements Download.
What should be checked instead
Donor eligibility and product quality. TEMCELL’s review describes medical-history assessment, examination and testing for infections including HIV, hepatitis B and C, HTLV and syphilis. It also describes product specifications covering identity, cell count, viability, sterility and endotoxin. These checks answer different questions from HLA matching: who supplied the cells, what the product contains and whether it meets release specifications 000215658.pdf.
For treatment under Japan’s Safety Act route, the donor rules call for history, examination and testing appropriate to the intended use, with repeat infection testing at an appropriate time where feasible to address the window period. These are separate legal provisions from TEMCELL’s product approval, not an extra universal testing rule for every approved MSC product T_doc?dataId=80ab4256&dataType=0&pageNo=1.
Infusion risks and contraindications. Ryoncil is contraindicated in patients with known hypersensitivity to DMSO or porcine or bovine proteins. Its label warns about acute infusion reactions, infectious-agent transmission and ectopic tissue formation, meaning tissue developing in an unintended location. Donor screening does not eliminate infection risk Download.
TEMCELL’s pooled 39-patient safety population had adverse reactions in 35 patients (89.7%) through week 52. The review’s definition included events for which a causal relationship could not be excluded; this is not proof that the cells caused every event. The patients had serious post-transplant disease, so the rate cannot be applied to an otherwise healthy person considering a clinic infusion 000215658.pdf. Assessing stem cell treatment safety in Japan requires the actual product and treatment plan, not just a “no matching” claim.
The regulatory route. For clinic treatment under Japan’s Act on the Safety of Regenerative Medicine, the relevant provision plan undergoes certified-committee review and submission procedures. Cell-processing facilities have separate requirements, which can involve permission, certification or notification depending on the facility. This route is distinct from product approval Index.
The registration and compliance distinction matters when reading a clinic’s documents: a filed provision plan is not proof of efficacy or approval for the claimed indication. MHLW publishes provider and plan information so patients can compare the provider, treatment name and review committee with what the clinic supplies 0000186471.
A practical consultation example
If a clinic offers donor MSCs for knee pain and says “no matching is needed,” ask for the exact product or protocol name before interpreting that answer. TEMCELL and Ryoncil’s GVHD approvals do not establish efficacy for knee pain. An autologous-versus-allogeneic label tells you whose cells are used, not whether the proposed treatment works for your diagnosis 000215658.pdfDownload.
If you also have an HLA antibody report or a future transplant plan, give those records to the treating specialist. Ask whether donor typing is available and whether further antibody testing would change the decision. This is a discussion prompt, not a claim that every MSC patient needs a crossmatch or that a negative result proves treatment is safe.
- What is the exact cell product, tissue source and route of administration?
- Is the treatment an approved product, an investigational study or a clinic service under a filed provision plan?
- What human evidence supports this product for my diagnosis, dose and route?
- Which donor-screening and batch-release results are available?
- Do my antibody results or transplant plans change the assessment?
- Who manages infusion reactions, and what follow-up is included?
Checking the proposed indications and contraindications alongside the product name and regulatory documents makes the consultation more useful. When choosing a treatment provider in Japan, ask who will explain any missing evidence before you agree to treatment.
Bottom line
TEMCELL and Ryoncil do not specify recipient–donor HLA matching as a treatment requirement. Donor testing still matters, and antibody concerns should be assessed in the context of the actual product, protocol and any future transplant. “No matching required” is not evidence that a treatment is risk-free or effective for another condition 000215658.pdfDownload.
Have questions about a proposed donor-cell treatment in Japan? Ask which product and regulatory documents apply.




